Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.88 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.88 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.88 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.88 |
| ▸ | PRKCG | P05129 | 1/20 | 0.88 |
| ▸ | PRKACA | P17612 | 1/20 | 0.88 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.88 |
| ▸ | AKT1 | P31749 | 1/20 | 0.88 |
| ▸ | GSK3A | P49840 | 1/20 | 0.88 |
| ▸ | GSK3B | P49841 | 1/20 | 0.88 |
| ▸ | PRKX | P51817 | 1/20 | 0.88 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.88 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.88 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.88 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.88 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.88 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.88 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3812691 | 0.94 | ROCK2 (1.00) | MMP13ROCK2ROCK1RPS6KA5MAP4K4 | |
| SCHEMBL30828595 | 0.94 | MMP13 (0.88) | MMP13ROCK2ROCK1RPS6KA5MAP4K4 | |
| SCHEMBL1161697 | 0.90 | MMP13 (0.82) | MMP13ROCK2ROCK1RPS6KA5MAP4K4 | |
| SCHEMBL539059 | 0.89 | EPHX2 (0.84) | MMP13ROCK2ROCK1RPS6KA5MAP4K4 | |
| SCHEMBL14082493 | 0.88 | MMP13 (0.79) | MMP13ROCK2ROCK1RPS6KA5MAP4K4 | |
| SCHEMBL29258253 | 0.88 | MMP13 (0.78) | MMP13ROCK2ROCK1RPS6KA5MAP4K4 | |
| SCHEMBL1569194 | 0.87 | ROCK2 (0.82) | MMP13ROCK2ROCK1RPS6KA5MAP4K4 | |
| SCHEMBL25718842 | 0.86 | ROCK2 (0.84) | MMP13ROCK2ROCK1RPS6KA5MAP4K4 | |
| SCHEMBL14082503 | 0.85 | ROCK2 (0.74) | MMP13ROCK2ROCK1RPS6KA5MAP4K4 | |
| Hydrochloric Acid SCHEMBL6461896 | 0.85 | MMP13 (0.74) | MMP13ROCK2ROCK1RPS6KA5MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081347-A1 | FUNCTIONALIZED AZABORINE COMPOUNDS AND AZABORINE-CONTAINING BIARYLCARBOXAMIDES, AND COMPOSITIONS AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT | 2017-03-23 | — | — | US | disclosed |
| US-20170081347-A1 | FUNCTIONALIZED AZABORINE COMPOUNDS AND AZABORINE-CONTAINING BIARYLCARBOXAMIDES, AND COMPOSITIONS AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT | 2017-03-23 | — | — | US | disclosed |
| WO-2015160688-A1 | FUNCTIONALIZED AZABORINE COMPOUNDS AND AZABORINE-CONTAINING BIARYLCARBOXAMIDES, AND COMPOSITIONS AND METHODS THEREOF | THE TRUSTEES OF BOSTON COLLEGE (US) | 2015-10-22 | — | — | WO | disclosed |
| EP-1836169-B1 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | KINEX PHARMACEUTICALS LLC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | RIB-X PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | PCNA, AADAC, MIF | MMP13 462/4885ROCK2 1325/4885ROCK1 1622/4885 |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | MMP13 4051/4885ROCK2 736/4885ROCK1 520/4885 |
| US-20170081347-A1 | FUNCTIONALIZED AZABORINE COMPOUNDS AND AZABORINE-CONTAINING BIARYLCARBOXAMIDES, AND COMPOSITIONS AND METHODS THEREOF | BRD7, BRD2, AADAC | MMP13 4082/4885ROCK2 3202/4885ROCK1 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.